Tag:

Bristol-Myers Squibb

Latest Headlines

Latest Headlines

Bristol-Myers licenses a second-line HIV drug for cheap copies in poor nations

Bristol-Myers Squibb agreed to license its HIV fighter Reyataz (atazanavir) to the Medicines Patent Pool, which will allow generics makers to turn out cheaper copies for sale in poor countries.

FDA panel throws dirt on Bristol-Myers' orphan drug metreleptin

Bristol-Myers Squibb's rare disease treatment metreleptin isn't up to snuff for its desired indication, an FDA committee voted, but agency advisers believe the drug shows some promise in a small subset of patients, giving the drug giant some hope for approval.

AZ, Bristol-Myers hopeful on dapagliflozin second try, but FDA staff remains wary

AstraZeneca and Bristol-Myers Squibb are heading back to the FDA with the once-spurned dapagliflozin, claiming they've addressed the diabetes drug's cancer risks, but agency staff remains wary of the treatment's dangers.

UPDATED: FDA still unconvinced on once-rejected diabetes drug from Bristol-Myers, AstraZeneca

AstraZeneca and Bristol-Myers Squibb are heading back to the FDA with the once-spurned dapagliflozin, claiming they've addressed the diabetes drug's cancer risks, but agency staff remains wary of the novel treatment's dangers.

FDA raises safety, efficacy questions for Bristol-Myers' rare-disease drug metreleptin

Bristol-Myers Squibb will go into its Wednesday panel session for the lipodystrophy drug metreleptin with an agency review that offers a grudging concession on signs of efficacy for a subgroup of patients along with some serious questions about potential safety issues and a number of criticisms for the way the clinical trial program was designed and executed.

Bristol-Myers, AstraZeneca get EU nod for diabetes drug

AstraZeneca and Bristol-Myers grabbed a win in the EU today for one of the drugs sprung from their diabetes treatment partnership. But the recommended approval comes even as questions have bubbled up about the future of that relationship.

Bristol-Myers rejigs top management to refocus commercial ops, beef up CFO role

Last week, Bristol-Myers Squibb said it would jettison some research programs, lay off workers and generally reorganize R&D. Now, CEO Lamberto Andreotti is rejigging the commercial side of the business. In the shuffle, current commercial chief Beatrice Cazala will be shunted aside, with current U.S. President Giovanni Caforio taking her place.

After Bristol-Myers R&D cuts, will AstraZeneca amp up its share of diabetes JV?

When Bristol-Myers Squibb reported earnings last week, it seemed fully committed to AstraZeneca and their multibillion-dollar diabetes joint venture. Sales growth there helped make up for hundreds of millions lost to generic competition. But now, Bristol-Myers says it's getting out of the diabetes discovery business. Will the company back away from its diabetes partnership next?

Bristol-Myers axing up to 75 R&D staffers, halts discovery work in three fields

Bristol-Myers Squibb joined the lineup of biopharma companies executing R&D realignments today, announcing plans to cut back on some of its discovery work in three key disease areas and eliminate 70 to 75 positions in its R&D group as it concentrates resources on late-stage programs.

Bristol-Myers scores first marketing application for all-oral hep C combo

In a notable first, Bristol-Myers Squibb has filed a combination of daclatasvir and asunaprevir for approval to treat hepatitis C in Japan--the first all-oral combo in a regulatory package that excludes interferon.